4-({(5R)-5-[(R)-([tert-butyl(dimethyl)silyl]oxy)(phenyl)methyl]pyrrolidin-2-yl}methyl)aniline | 1190391-56-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-({(5R)-5-[(R)-([tert-butyl(dimethyl)silyl]oxy)(phenyl)methyl]pyrrolidin-2-yl}methyl)aniline
• 英文别名: 4-({(5R)-5-[(R)-([tert-butyl(dimethyl)silyl]oxy}(phenyl)methyl]pyrrolidin-2-yl)methyl)aniline；4-[[(5R)-5-[(R)-[tert-butyl(dimethyl)silyl]oxy-phenylmethyl]pyrrolidin-2-yl]methyl]aniline
• CAS: 1190391-56-0
• 化学式: C₂₄H₃₆N₂OSi
• 分子量: 396.648
• InChiKey: FCKGESYAHWACQR-XMCWYHTOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  47.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-({(5R)-5-[(R)-([tert-butyl(dimethyl)silyl]oxy)(phenyl)methyl]pyrrolidin-2-yl}methyl)aniline 在 四丁基氟化铵 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 (2S,5R)-tert-butyl 2-(4-aminobenzyl)-5-((R)-hydroxy(phenyl)methyl)pyrrolidine-1-carboxylate
  参考文献：
  名称：

  Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective human β3 adrenergic receptor agonists

  摘要：

  A novel class of human beta(3)-adrenergic receptor agonists was designed in effort to improve selectivity and metabolic stability versus previous disclosed beta(3)-AR agonists. As observed, many of the beta(3)-AR agonists seem to need the acyclic ethanolamine core for agonist activity. We have synthesized derivatives that constrained this moiety by introduction of a pyrrolidine. This unique modification maintains human beta(3) functional potency with improved selectivity versus ancillary targets and also eliminates the possibility of the same oxidative metabolites formed from cleavage of the N-C bond of the ethanolamine. Compound 39 exhibited excellent functional beta(3) agonist potency across species with good pharmacokinetic properties in rat, dog, and rhesus monkeys. Early de-risking of this novel pyrrolidine core (44) via full AMES study supports further research into various new beta(3)-AR agonists containing the pyrrolidine moiety. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.087
• 作为产物：
  描述：

  benzyl {4-[(3E,5R,6R)-5-{[(benzyloxy)carbonyl]amino-6-[tert-butyl(dimethyl)silyl]oxy}-6-(3-chlorophenyl)-2-oxohex-3-en-1-yl]phenyl}carbamate 在 palladium 10% on activated carbon 氢气 作用下， 以 乙醇 为溶剂， 反应 1.0h， 以66%的产率得到4-({(5R)-5-[(R)-([tert-butyl(dimethyl)silyl]oxy)(phenyl)methyl]pyrrolidin-2-yl}methyl)aniline
  参考文献：
  名称：

  HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS

  摘要：

  本发明提供了式(I)的化合物，其药物组成物以及使用该化合物在治疗或预防由β3-肾上腺素受体激活介导的疾病的方法。

  公开号：

  US20090253705A1

文献信息

• [EN] COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONIST AND AN ANTIMUSCARINIC AGENT<br/>[FR] POLYTHÉRAPIE UTILISANT UN AGONISTE DES RÉCEPTEURS ADRÉNERGIQUES BÊTA-3 ET UN AGENT ANTIMUSCARINIQUE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011043942A1

  公开（公告）日：2011-04-14

  Described herein is an improved method of treating overactive bladder, wherein the method comprises administering to a patient in need thereof a beta 3 adrenergic receptor agonist, an antimuscarinic agent, and an optional selective M2 antagonist. Such combination therapy provides improved efficacy and/or reduced side effects.

  本文描述了一种改进的治疗过度活跃膀胱的方法，其中该方法包括向需要的患者施用β3肾上腺能受体激动剂、抗胆碱药物和可选的选择性M2拮抗剂。这种联合疗法提供了改善的疗效和/或减少的副作用。
• HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS
  申请人：Berger Richard

  公开号：US20090253705A1

  公开（公告）日：2009-10-08

  The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

  本发明提供了式(I)的化合物，其药物组成物以及使用该化合物在治疗或预防由β3-肾上腺素受体激活介导的疾病的方法。
• COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONISTS AND AN ANTIMUSCARINIC AGENT
  申请人：Edmondson Scott D.

  公开号：US20120202819A1

  公开（公告）日：2012-08-09

  Described herein is an improved method of treating overactive bladder, wherein the method comprises administering to a patient in need thereof a beta 3 adrenergic receptor agonist, an antimuscarinic agent, and an optional selective M 2 antagonist. Such combination therapy provides improved efficacy and/or reduced side effects.

  本文描述了一种改进的治疗过度活跃膀胱的方法，其中该方法包括向需要治疗的患者施用β3肾上腺素能受体激动剂、抗胆碱药物和可选的选择性M2拮抗剂。这种联合治疗提供了更好的疗效和/或减少了副作用。
• Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
  申请人：Berger Richard

  公开号：US08653260B2

  公开（公告）日：2014-02-18

  The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

  本发明提供了式（I）的化合物，其药物组成物，以及使用它们治疗或预防由β3-肾上腺素能受体激活介导的疾病的方法。
• Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists
  申请人：Merck Sharp & Dohme Corp.

  公开号：US08247415B2

  公开（公告）日：2012-08-21

  The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

  本发明提供了式(I)的化合物、其制药组合物以及使用该化合物治疗或预防由β3-肾上腺素受体激活介导的疾病的方法。